Lineagen Inc.

2677 E Parleys Way
Salt Lake City, Utah 84109-1617, USA
View Map

Telephone: USA [1] 801-931-6200
Fax: USA [1] 801-931-6201

Send us a message

Close X

Press Releases

February 26, 2014

Lineagen Announces Identification of 39 Genetic Variants as Novel Risk Factors for Developing Autism Spectrum Disorder (ASD)

Unique research approach in ASD may lead to more powerful genetic diagnostic tests. Findings appear in the current issue of Molecular Autism.

January 14, 2013

Lineagen Announces New Study Demonstrating Two-Fold Increase in Detection Rate of Validated Genetic Variants in Individuals with Autism Spectrum Disorders

Study also identifies gene regions that have relevance to drug development programs and indicates potential use as companion diagnostics in autism spectrum disorders. Results appear in the current issue of PLOS ONE

December 3, 2012

CARD and Lineagen Offer FirstStepDx® Genetic Testing and Counseling for Children on the Autism Spectrum

Individuals receiving the world’s most advanced treatment for autism spectrum disorders (ASDs) at CARD will now be offered the most comprehensive clinical genetic testing service available.

May 17, 2012

Lineagen Completes 9000-Person Study Focused on Genetic Variants in Individuals Diagnosed with Autism Spectrum Disorder (ASD)

Lineagen's next-generation FirstStepDx® genetic test to incorporate novel variants; launch planned for as early as fourth quarter of 2012

March 29, 2012

Lineagen Presents Data Showing Clinical Utilization of FirstStepDx®, a New Model of Genetic Service Delivery, at the 2012 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

FirstStepDx Combines Highly Advanced Genetic Testing and Counseling Services to Aid in the Diagnostic Evaluation and Clinical Management of Children with Developmental Delay and Autism Spectrum Disorders

March 28, 2012

Lineagen Applies Affymetrix' GeneChip® Technology to Next-Generation FirstStepDx® Service for Individuals with Developmental Delay and Autism Spectrum Disorders

SANTA CLARA, California and SALT LAKE CITY, Utah -- March 28, 2012 -- Affymetrix, Inc. (NASDAQ: AFFX) and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip® technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).  The new FirstStepDx offering is anticipated to be available by mid-2012 and will feature a proprietary microarray-based assay incorporating novel genetic markers from recently concluded studies of more than 10,000 individuals.

December 14, 2011

Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis

Funding to Lineagen will Support Clinical Program in Collaboration with the University of Utah to Develop and Validate a Broad Array of Diagnostic and Prognostic Strategic Tools

January 10, 2011

Lineagen Launches FirstStepDx Genetic Testing and Counseling Service to Help Physicians Diagnose Autism and Developmental Delay Earlier

  • FirstStepDx genetic testing and counseling service empowers physicians with tools to enhance and accelerate the diagnostic evaluation of children with indications of autism spectrum disorders (ASD) or developmental delay (DD)
  • ASD is the fastest-growing neurodevelopmental disability in the U.S., affecting approximately 1 in 110 children, including up to 1 in 58 boys
  • FirstStepDx employs advanced standard of care technology combined with genetic counseling and consultative services
  • Families describe ‘life-changing’ impact of FirstStepDx
 

January 4, 2011

Lineagen CEO Michael Paul to Present Series B Update and Accelerated Demand for Genetic Testing and Counseling Services at 2011 Biotech Showcase

  • Supported by key medical organization recommendation, Lineagen genetic testing and counseling services are experiencing strong demand from physicians
  • Company to present an update of its current $15 Million Series B funding round
  • Third annual Biotech Showcase is anticipated to attract 800 top investment and industry leaders

October 4, 2010

Lineagen, Inc. to Showcase $15 Million Series ‘B’ Round at the 9th Annual BIO Investor Forum

Lineagen Looks to Close $10 Million of New Commitments in Addition to $5 Million by Current Series ‘A’ Investors, Sanderling Ventures, vSpring Capital, PrairieGold Venture Partners and Mesa Verde Venture Partners

September 2, 2010

Lineagen, Inc. Selected to Present at the 2010 Genetic Risk Factors for Autism: Translating Discoveries into Diagnostics Symposium in Toronto

Dr. Michael S. Paul, the Company’s President & Chief Executive Officer, was selected to present at the “Genetic Risk Factors for Autism: Translating Discoveries into Diagnostics” symposium.

October 7, 2010

M-CHAT.org launched by Lineagen to accelerate in-office M-CHAT screening of children for signs of Autism Spectrum Disorders

Lineagen, Inc. announces M-CHAT.org, the first fully automated, online version of the Modified Checklist for Autism in Toddlers (M-CHAT), as a new community tool to help families and physicians make the autism screening process more efficient.

October 5, 2010

Lineagen, Inc. Announces Burt De Mill to Lead Commercial Team

Burt De Mill, formerly Senior Vice President Sales & Marketing at Genoptix Medical Laboratories, joins Lineagen to lead commercial expansion of diagnostic services for Autism Spectrum Disorders.

August 30, 2010

Lineagen, Inc. Closes $5 Million to Complete $10.8 Million Series A Round

New Investor PrairieGold Venture Partners Joins Existing Institutional Investor Line-up of Sanderling Ventures, vSpring Capital and Mesa Verde Venture Partners